Evidence map›Paper›PMID 35506437›Full record

ArticleMolecular medicine reports2022

Knockdown of CDCA5 suppresses malignant progression of breast cancer cells by regulating PDS5A.

Yang Wang, Jian Yao, Yulin Zhu, Xuejiao Zhao, Jing Lv, Fulan Sun

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. TubularInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yang WangYun Kang School of Medicine and Health, NanFang College, Guangzhou, Guangdong 510970, P.R. China.
Jian YaoYun Kang School of Medicine and Health, NanFang College, Guangzhou, Guangdong 510970, P.R. China.
Yulin ZhuYun Kang School of Medicine and Health, NanFang College, Guangzhou, Guangdong 510970, P.R. China.
Xuejiao ZhaoYun Kang School of Medicine and Health, NanFang College, Guangzhou, Guangdong 510970, P.R. China.
Jing LvYun Kang School of Medicine and Health, NanFang College, Guangzhou, Guangdong 510970, P.R. China.
Fulan SunDepartment of Thyroid and Breast Surgery, The Second People's Hospital of Nantong, Nantong, Jiangsu 226000, P. R. China.
Nanfang Hospital · CNNanfang College GuangzhouSecond People's Hospital of NanTong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of the most common malignant tumors in women. Cell division cycle‑associated 5 (CDCA5) is closely associated with the behavior of various cancer types. The aim of the present study was to explore the effect of CDCA5 on breast cancer. Western blot analysis and reverse transcription‑quantitative PCR were used to detect the expression level of CDCA5 in human normal mammary cells and human breast cancer cell lines. To determine its function in MDA‑MB‑231 cells, CDCA5 was silenced in MDA‑MB‑231 cells by transient short hairpin RNA transfection. Cell Counting Kit‑8 and clonogenicity assays were used to evaluate cell proliferation. Wound healing and Transwell assays were used to detect cell invasion and migration. Western blot analysis was used to detect the protein expressions of Ki67 and PCNA associated with proliferation, MMP2 and MMP9 associated with migration. CDCA5 was found to be markedly increased in breast cancer cell lines. CDCA5 knockdown was able to suppress cell proliferation, invasion and migration. CDCA5 inhibition downregulated PDS5 cohesin‑associated factor A (PDS5A) expression in breast cancer cells. PDS5A overexpression was found to reverse the effect of CDCA5 inhibition on breast cancer cell proliferation and migration. CDCA5 knockdown was shown to suppress the malignant progression of breast cancer cells by regulating PDS5A. The present findings may provide new potential targets for breast cancer therapy.

Indexed as

Adaptor Proteins, Signal TransducingBreast NeoplasmsCell Cycle ProteinsNuclear ProteinsCell CycleCell Line, TumorCell ProliferationFemaleHumansMCF-7 CellsAdaptor Proteins, Signal TransducingCDCA5 protein, humanCell Cycle ProteinsNuclear ProteinsPDS5A protein, humanbreast cancercell division cycle associated 5cell invasioncell migrationcell proliferationPDS5 cohesin‑associated factor A

Identifiers

PMID35506437
PMCPMC9133959
OpenAlexW4225396402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.